在接受安洛丁尼布治疗的晚期肺癌患者中新发作的心律失常
Conghui Shang1, Hao Wang1, Jindong Chen1
1Department of Cardiology, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
在晚期肺癌患者中,安洛丁尼布可以引起新发性心律失常 (NOA),特别是在联合疗法中. 然而,这些心律失常通常不会影响整体存活率,年龄和糖尿病是关键预测因素.
科学领域:
- 在瘤学瘤学.
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 安洛丁尼布用于晚期肺癌 (ALC).
- 安洛丁尼布的前节律失常风险尚未得到充分确立.
- 了解新发性心律失常 (NOA) 及其影响至关重要.
研究的目的:
- 用anlotinib治疗的ALC患者的NOA的特征.
- 为了确定NOA的预测因素.
- 评估NOA对ALC患者结局的影响.
主要方法:
- 对922名用anlotinib治疗的ALC患者的回顾性研究 (2017年5月至2021年11月).
- 通过电图/Holter识别的NOA;使用AE的常用术语标准进行分级.
- 预测因子的后勤回归;整体生存的卡普兰-梅尔.
主要成果:
- NOA发生在22.6%的患者中,最常见的是QT延长 (57.7%) 和过早收缩 (28.4%).
- 联合治疗 (29.9%) 与单一治疗 (10.9%) 的NOA发病率更高.
- 独立预测因素包括年龄,糖尿病,PD-1抑制剂和基药物;NOA对整体存活率的影响最小.
结论:
- 安洛丁尼布可以在ALC患者中引起NOA,QT延长是常见的.
- 同时治疗和患者年龄和糖尿病等因素会增加NOA的风险.
- 尽管发生,但NOA似乎对ALC患者的整体存活率产生良性影响.
更多相关视频
09:32Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
Published on: October 17, 2025
08:03Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation
Published on: October 20, 2022
相关概念视频
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Disturbances in Heart Rhythm
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
Dysrhythmias VII: Nursing Management of Dysrhythmias
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
